ArticleJournal of the Endocrine Society2025
Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Is MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions.Diabetologia · 2026Review
- High Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics.Diabetes, obesity & metabolism · 2026Article
- Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease.The Lancet regional health. Europe · 2026Article
- Liver fibrosis burden and risk of incident arrhythmia in metabolic dysfunction-associated steatotic liver disease.Scientific reports · 2026Article
- Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines.Diabetes, obesity & metabolism · 2026Review
- Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes.JAMA network open · 2026Article
- Association between vitamin D and metabolic-associated steatotic liver disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Article
- Primary Human Tissue Models for Metabolic Dysfunction-Associated Liver Disease - toward Streamlining Drug Discovery with Patient-Derived Assays.Advanced biology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objective: We aimed to evaluate recent changes in the prevalence of steatotic liver disease, its subtypes, and liver fibrosis among US adults with and without diabetes between 2017-2020 and 2021-2023. Research Design and Methods: In this serial cross-sectional study, we assessed adults aged ≥18 years with complete vibration-controlled transient elastography (Fibroscan®) data from the National Health and Nutrition Examination Surveys from 2017-2020 and 2021-2023. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined as liver steatosis in the presence of 1 cardiometabolic risk factor. Results: A total of 13 153 adults (n = 7683 from 2017-2020; n = 5470 from 2021-2023) were included. The prevalence of MASLD significantly decreased from 37.6% to 32.5% in this period ( Conclusion: Despite the evidence of a decline in MASLD prevalence, rates of liver fibrosis and cirrhosis are rising, especially in individuals with diabetes. This underscores the need for improved screening of liver fibrosis, early initiation of effective pharmacological therapies, and aggressive management of related cardiometabolic conditions in individuals with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.